MDS (Canada) Inc. v. Rad Source Technologies, Inc.

Procedural entryThis page is a short order in MDS (Canada) Inc. v. Rad Source Technologies, Inc.. Read the opinion of the Court — 720 F.3d 833
Court of Appeals for the Eleventh Circuit·Decided July 1, 2013·No. 11-15145·Published

Opinion

Case: 11-15145 Date Filed: 07/01/2013 Page: 1 of 61

[PUBLISH]

IN THE UNITED STATES COURT OF APPEALS

FOR THE ELEVENTH CIRCUIT ________________________

No. 11-15145 ________________________

D.C. Docket No. 0:09-cv-61652-ASG

MDS (CANADA) INC., a Canadian corporation, BEST THERATRONICS, LTD., a Canadian corporation, BEST MEDICAL INTERNATIONAL, INC., a.k.a. Beast Medical International, Inc.,

Plaintiffs - Counter Defendants - Appellants,

versus

RAD SOURCE TECHNOLOGIES, INC., a Florida corporation,

Defendant - Counter Claimant - Appellee.

________________________

Appeal from the United States District Court for the Southern District of Florida ________________________

(July 1, 2013) Case: 11-15145 Date Filed: 07/01/2013 Page: 2 of 61

Before DUBINA, Chief Judge, PRYOR and ANDERSON, Circuit Judges.

PER CURIAM:

This appeal presents a jurisdictional issue of first impression in our Court:

whether the Federal Circuit has exclusive jurisdiction to hear an appeal of a breach

of contract claim that would require the resolution of a claim of patent

infringement for the complainant to succeed. We conclude that this Court does

have appellate jurisdiction. We then address the merits of this breach of contract

claim, discuss the district court’s findings of facts and conclusions of law after the

bench trial, and affirm in part and certify a question to the Florida Supreme Court.

I. BACKGROUND

Rad Source Technologies is a Florida corporation with its principal place of

business in Georgia. It specializes in research and development of irradiation

technologies and participated in the development of the technology contained in

the RS 3000 blood irradiation device. Blood is irradiated to eliminate pathogens

and other microbes in blood to, among other things, reduce the risk of Graft Versus

Host Disease (a common side effect in transplants). Rad Source’s device replaced

radioactive isotopes with X-rays as the means of irradiating the blood and was the

first to do so. Rad Source developed its first product, the RS 3000, in the late

1990s, and received FDA approval in 1998. Rad Source manufactured and sold

the RS 3000 in 1999 as a one blood bag device, but by 2001 had changed the

2 Case: 11-15145 Date Filed: 07/01/2013 Page: 3 of 61

device to hold 2 or 3 bags. Until August 2003, Rad Source sold the RS 3000 for

$110,000 to $120,000.

Rad Source obtained three patents for its work in connection with the RS

3000. These patents were U.S. Patent Nos. 6,212,255 (the '255 patent), 6,489,099

(the '099 patent), and 6,614,876 (the '876 patent). These three patents are the

patents to which the License Agreement between the parties refers.

Rad Source began work on a different type of technology in the late 1990s

that would generate high doses of X-ray radiation through a long tube or

cylindrical anode with an electron emitter centered through its entire length to

generate a field of X-rays in three dimensions. Rad Source obtained two patents

related to this long tube technology, the '147 and the '686.

In the late 1990s, Rad Source approached MDS Nordion, now known as

Nordion and referred to throughout this opinion as Nordion, about the RS 3000 but

Nordion was not interested. Nordion is a Canadian company with a specialty in

the detection, prevention, and diagnosis of disease. Nordion sold gamma-source

blood irradiators and other irradiation products worldwide, but had no knowledge

or focus on X-ray technology.

After 2002, when sales of the RS 3000 had increased, Nordion approached

Rad Source about acquiring an interest in the RS 3000. Because Rad Source did

not have the funding to launch the RS 3000 internationally as it desired, it was

3 Case: 11-15145 Date Filed: 07/01/2013 Page: 4 of 61

interested. Further, Rad Source’s resources were tied up in further development of

X-ray technologies, including the long tube technology. Because of Nordion’s

expertise in irradiation, Rad Source thought that a partnership would be a good fit.

But Nordion stated that it was not yet interested in the long tube technology.

On August 20, 2003, Rad Source and Nordion entered the License

Agreement that is the focus of this dispute. The negotiation for the agreement had

lasted over a year. The Food and Drug Administration cleared Nordion to market

and sell the RS 3000 in the United States on September 26, 2003, and that date

served as the closing date for the License Agreement. Nordion thereafter began

marketing the RS 3000 as the “Raycell.”

Rad Source received $1.7 million as compensation under the Agreement.

The term of the license extended from the closing date until the last of the patents

expired in 2022, and Rad Source agreed in effect to receive compensation only in

the first four years of the Agreement, although Rad Source could receive

compensation in the fifth year if Nordion sold more than forty systems that year.

In 2007, Rad Source employees saw Nordion employees at a conference and

indicated that the long tube technology was ready to be revisited. At the invitation

of Rad Source, Nordion employee Carolin Vandenberg visited Rad Source’s

facilities outside of Atlanta with two other Nordion employees in July 2007. The

district court found that Rad Source showed the Nordion employees some devices

4 Case: 11-15145 Date Filed: 07/01/2013 Page: 5 of 61

using the long tube technology in applications other than blood irradiation and

spoke about whether the long tube technology had any application in blood

irradiation. Rad Source heard from Nordion again in September when Rad

Source’s president, Randol Kirk, emailed Vandenberg about irradiation news and

received a response from Vandenberg that seemed to suggest interest; she sought

“a company profile, with some level of financials, if possible, that I can forward”

and for his availability over the next few weeks. Rad Source provided the

information in October, but never heard back from Nordion.

In November 2007, Nordion and Best Medical (“Best”) executed an “Asset

Purchase Agreement” for the sale of Nordion’s External Beam Therapy and Self

Contained Irradiator business for approximately $15 million. The closing of the

agreement was conditioned on the execution of a non-compete clause by Nordion

and the consent of about twenty-five companies to the assignment of their Nordion

contracts to Best.

In December 2007, Nordion requested that Rad Source consent to an

assignment of the License Agreement to Best. Rad Source was completely taken

aback by the news of the agreement between Nordion and Best, in light of the

recent visit by Vandenberg, and refused to consent. Rad Source stated that the

assignment would not be in Rad Source’s best economic or business interest, but

5 Case: 11-15145 Date Filed: 07/01/2013 Page: 6 of 61

asked for the documents pertaining to the sale and said that it would reconsider the

transaction. Nordion did not provide the information.

The parties participated in a conference call in January 2008 to discuss the

request for consent to assignment. Nordion told Rad Source that it would

sublicense its rights under the contract to Best if Rad Source did not consent. Rad

Source protested that Nordion did not have that right and continued to oppose the

assignment.

Free access — add to your briefcase to read the full text and ask questions with AI

MDS (Canada) Inc. v. Rad Source Technologies, Inc., (11th Cir. 2013).

MDS (Canada) Inc. v. Rad Source Technologies, Inc. (MDS (Canada) Inc. v. Rad Source Technologies, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

University of South Alabama v. American Tobacco Co.
168 F.3d 405 (Eleventh Circuit, 1999)
Access Now, Inc. v. Southwest Airlines Co.
385 F.3d 1324 (Eleventh Circuit, 2004)
United States v. Richard Junior Frazier
387 F.3d 1244 (Eleventh Circuit, 2004)
Graver Tank & Mfg. Co. v. Linde Air Products Co.
339 U.S. 605 (Supreme Court, 1950)
Christianson v. Colt Industries Operating Corp.
486 U.S. 800 (Supreme Court, 1988)
Warner-Jenkinson Co. v. Hilton Davis Chemical Co.
520 U.S. 17 (Supreme Court, 1997)
Empire Healthchoice Assurance, Inc. v. McVeigh
547 U.S. 677 (Supreme Court, 2006)
Wms Gaming Inc. v. International Game Technology
184 F.3d 1339 (Federal Circuit, 1999)
Gunn v. Minton
133 S. Ct. 1059 (Supreme Court, 2013)
Estate of Basile v. Famest, Inc.
718 So. 2d 892 (District Court of Appeal of Florida, 1998)
Leesburg Cancer Center v. Leesburg Regional
972 So. 2d 203 (District Court of Appeal of Florida, 2007)
Fireman's Fund Insurance Company v. Vogel
195 So. 2d 20 (District Court of Appeal of Florida, 1967)
Department of Revenue v. Bank of America
752 So. 2d 637 (District Court of Appeal of Florida, 2000)
WSG WEST PALM BEACH DEVELOPMENT, LLC v. Blank
990 So. 2d 708 (District Court of Appeal of Florida, 2008)